BREAKING
Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens 19 hours ago Earnings Summary: A snapshot of Smith+Nephew’s (SNN) Q4 2025 report 20 hours ago Earnings Summary: Norwegian Cruise Line (NCLH) Q4 FY25 revenue rises 6% 21 hours ago Earnings Summary: Highlights of Calumet’s (CLMT) Q4 2025 earnings report 4 days ago Zoom Communications Q4 2025 Earnings Results 5 days ago Agilent Q1 Revenue Rises 7%, Net Income Declines 5 days ago Synopsys Q1 2026 Earnings Results 5 days ago Key highlights from J.M. Smucker’s (SJM) Q3 2026 earnings results 5 days ago Hormel Foods (HRL) Q1 2026 Earnings: Key financials and quarterly highlights 5 days ago Key metrics from Lowe’s (LOW) Q4 2025 earnings results 6 days ago Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens 19 hours ago Earnings Summary: A snapshot of Smith+Nephew’s (SNN) Q4 2025 report 20 hours ago Earnings Summary: Norwegian Cruise Line (NCLH) Q4 FY25 revenue rises 6% 21 hours ago Earnings Summary: Highlights of Calumet’s (CLMT) Q4 2025 earnings report 4 days ago Zoom Communications Q4 2025 Earnings Results 5 days ago Agilent Q1 Revenue Rises 7%, Net Income Declines 5 days ago Synopsys Q1 2026 Earnings Results 5 days ago Key highlights from J.M. Smucker’s (SJM) Q3 2026 earnings results 5 days ago Hormel Foods (HRL) Q1 2026 Earnings: Key financials and quarterly highlights 5 days ago Key metrics from Lowe’s (LOW) Q4 2025 earnings results 6 days ago
ADVERTISEMENT
Market News

Titan Pharmaceuticals, Inc. (TTNP): Q4 2019 Earnings Snapshot

— Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) reported a loss of $0.08 per share in the fourth quarter of 2019, in line with Wall Street expectation. — Q4 revenue was flat at $1.2 million, vs. $920,000 expected. — As at December 31, 2019, Titan had cash and cash equivalents of approximately $5.2 million. — Launch of […]

$TTNP March 30, 2020 1 min read
NYSE
$TTNP · Earnings

— Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) reported a loss of $0.08 per share in the fourth quarter of 2019, in line with Wall Street expectation. — Q4 revenue was flat at $1.2 million, vs. $920,000 expected. — As at December 31, 2019, Titan had cash and cash equivalents of approximately $5.2 million. — Launch of […]

· March 30, 2020

— Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) reported a loss of $0.08 per share in the fourth quarter of 2019, in line with Wall Street expectation.

— Q4
revenue was flat at $1.2 million, vs. $920,000 expected.

Earnings Update by AlphaStreet

— As
at December 31, 2019, Titan had cash and cash equivalents of approximately $5.2
million.

— Launch
of Sixmo may be delayed due to the impact of Covid-19.

— TTNP
shares gained 4.4% during after-market trading hours.

ADVERTISEMENT
ADVERTISEMENT